Background Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …

Background RET fusions are present in 1%–2% of non-small cell lung cancer (NSCLC).
Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET inhibitor …

* Includes 11 patients with prior treatment other than platinum.† Includes 10 patients with
prior treatment other than platinum.‡ includes 2 patients still on treatment with PRs pending …

The recent approvals by the Food and Drug Administration several tumor-agnostic drugs
have resulted in a paradigm shift in cancer treatment from an organ/histology-specific …

Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …

Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of
RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate …

Background Rearranged during transfection (RET) gene fusions are a validated target in
non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and …

Simple Summary Non-small cell lung cancer (NSCLC) remains a significant cause of death
worldwide, despite the significant progresses to date. Multiple molecular alterations have …

• Recent tumor-agnostic drug approvals have resulted in a paradigm shift in cancer
treatment away from organ/histology specific indications to biomarker-guided tumor-agnostic …

PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …